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INTRODUCTION: The DiGeorge Syndrome was first described in 1968 as a primary immunodeficiency resulting from
the abnormal development of the third and fourth pharyngeal pouches during embryonic life. It is characterized by
hypocalcemia due to hypoparathyroidism, heart defects, and thymic hypoplasia or aplasia. Its incidence is 1:3000 live
births and, despite its high frequency, little is known about its natural history and progression. rThis is probably
due to diagnostic difficulties and the great variety of names used to describe it, such as velocardiofacial, Shprintzen,
DiGeorge, and CATCH 22 Syndromes, as well as conotruncal facial anomaly. All represent the same genetic
condition, chromosome 22q11.2 deletion, which might have several clinical expressions.
OBJECTIVES: To describe clinical and laboratorial data and phenotypic characteristics of patients with DiGeorge
Syndrome.
METHODS: Patients underwent standard clinical and epidemiological protocol and tests to detect heart diseases,
facial abnormalities, dimorphisms, neurological or behavioral disorders, recurrent infections and other comorbid-
ities.
RESULTS: Of 14 patients (8m – 18y11m), only one did not have 22q11.2 deletion detected. The main findings were:
conotruncal malformation (n = 12), facial abnormalities (n = 11), hypocalcemia (n = 5) and low lymphocyte count
(n=2).
CONCLUSION: The authors pointed out the necessity of DGS suspicion in all patient presenting with heart defects,
facial abnormalities (associated or not with hypocalcemia), and immunological disorders because although
frequency of DGS is high, few patients with a confirmed diagnosis are followed up.
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INTRODUCTION
In spite of the high frequency of DiGeorge Syndrome
(DGS), the commonest chromosome deletion syndrome, its
diagnosis is often not suspected. Variable clinical pheno-
types and different abnormalities may be caused by 22q11.2
deletion: thymus dysfunction, cardiac diseases, immunode-
ficiency, and other clinical problems.
1 In our country, few
cases have been reported, but the clinical phenotypes
associated with DiGeorge Syndrome should be well known
so that patients receive an early diagnosis and correct
treatment.
2,3
Most patients with DGS have a partial form of the disease
and thymic hypoplasia. This defect results in cellular
immunodeficiency, although humoral defects have also
been described. Autoimmune diseases have been associated
with DGS, probably in consequence of T cell regulatory
defects and impaired central tolerance.
4
Cardiac abnormalities, mainly conotruncal defects, have
been found in DGS, and several authors have pointed out
that isolated congenital heart disease may be associated
with it.
5
Parathyroid dysfunction may cause hypocalcemia and
seizures in the neonatal period. This is considered a
warning sign suggestive of DGS. Several authors recom-
mend that newborns undergo screening for lymphopenia,
which may assist in the early diagnosis of severe combined
immunodeficiency and DGS.
6
Most DGS patients are hemizygous for a 3Mb region on
human chromosome 22 while others have a smaller 1.5Mb
nested deletion. These observations suggest that haploin-
sufficiency of one or more genes on human chromosome 22
are responsible for its etiology. This study describes the
most important clinical phenotypes resulting from DGS and
draws attention to the frequency of this disease and its
diagnosis.
Copyright  2010 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
CLINICS 2010;65(9):865-869 DOI:10.1590/S1807-59322010000900009
865METHODS AND MATERIALS
Fourteen (14) patients with DGS were evaluated (8 males).
The mean age was 8y10m (8m – 18y11m). All patients met
the following inclusion criteria: small or normal number of
circulating T cells, normal number of circulating B cells,
normal or low serum immunoglobulin level, hypoparathyr-
oidism, conotruncal defect, facial abnormalities, and 22q11.2
or 10p deletions.
7 The patients were referred from the
Genetic Unit and Instituto do Corac ¸a ˜o of Hospital das
Clı ´nicas of Universidade de Sa ˜o Paulo (HC-FMUSP), Sa ˜o
Paulo, Brazil. This study was approved by the Ethics
Committee of the institution where it was conducted, and
all patients and controls signed an informed consent to
participate in this study.
Clinical evaluation
All patients underwent a clinical and epidemiological
protocol to collect information about personal characteristics
and history, family history, heart disease, facial abnormal-
ities, dimorphisms, neurological or behavioral disorders,
recurrent infections, and other comorbidities. Patients were
examined by the same investigators (an immunologist and a
geneticist) and their anthropometric measurements were
recorded.
Laboratory tests
The levels of serum triiodothyronine (T3), thyroxin (T4),
free thyroxin (FT4), TSH, and thyroid antibodies (thyroglo-
bulin and peroxidase) were measured. Parathyroid hor-
mone, ionic or total calcium, and phosphorus levels were
also measured. All patients had a complete blood count,
and the Comans-Bitter values were used as reference to
lymphocytes.
8
Detection of 22q11.2 deletion
Eight (8) patients (described in Table 1) had microdele-
tions in 22q11.2, detectable only by FISH (Fluorescence In
Situ Hybridization), a technique that integrates the use of
classical cytogenetics with molecular genetics, using DNA
probes labeled with fluorescent material that identify
specific regions of the genome.
9,10 Two (2) were used as
probes for this analysis: the N25 (which hybridizes at
D22S75, located within the region commonly deleted in
SD22q11) and TUPLES 1 (which binds to any gene TUPLES
and a part of the DNA located close to their ends).
The lost of heterozygosity detected by these markers
could be used as a real tool of diagnosis in patients
suspected of SD22q11. Gioli-Pereira et al.,
11 researching
SNPs (single nucleotide polymorphisms) located in 22q11.2,
in a Brazilian population, found these markers are efficient
to determine the loss of heterozygosity in up to 92.9% of
cases. Five (5) patients (IGBS, MASS, ASI, CSS and TPS)
were referred from Instituto do Corac ¸a ˜o, their mutations
having been detected by the SNPs technique following the
procedures described by Gioli-Pereira et al.
11
RESULTS
Table 1 shows clinical and laboratory data regarding
diagnostic criteria. One patient (ABARS) did not have
22q11.2 deletion. She was included in the study because she
metothercriteriaatthetimeofdiagnosis:hypocalcemia,facial
dimorphism, and lymphopenia, according to Notarangelo
et al.
7
Isolated or combined cardiac malformations were the
most frequent findings, and 12 patients (86%) were affected
with the followed distributions: 5 had tetralogy of Fallot; 5
ventricular septal defect (3 isolated and 2 associated with
atrial septal defects); 1 isolated transposition of great
vessels; 1 aortic arch disruption associated with septal
defects; 1 truncus arteriosus associated with septal defects;
and 1 pulmonary atresia. Only 4 patients did not need to
undergo surgical correction of these malformations.
Eleven (11) patients (85.7%) had facial dimorphisms, and
the most prevalent were oral defects, alone or in combina-
tions. Microstomia was found in 64.3% (9/14) of the
patients, and 57.2% (8/14) had palate defects, micrognathia,
and short stature. Elongated fingers were observed in 50%
of the patients; straight facial profile, dental abnormalities
and over-folded ear helix in 42.8% (6/14); hypertelorism in
35.8% (5/14); and strabismus in 21.5% (3/14). One patient
had a congenital clubfoot, which was corrected surgically
before this study.
Seven (7) patients had recurrent infections, mainly
pneumonia, and only one of them was free of any cardiac
defect that might explain lung infections. Most infections
Table 1 - Diagnostic criteria in 14 patients with DGS.
Patient Sex Age
22q11.2 deletion
Methodology Conotruncal Defect HypoCa++ Facial Abnorm. Lymphopenia
1 M 17y 2m Yes/FISH VSD No Yes No
2 M 11y 10m Yes/SNP Tetralogy of Fallot No Yes No
3 M 2y 4m Yes/FISH Tetralogy of Fallot Yes No Yes
4 M 4y Yes/FISH Transposition of great vessels No No Yes
5 M 8y 9m Yes/SNP Tetralogy of Fallot No No No
6 F 5y 5m Yes/FISH VSD No Yes No
7 M 9y 9m Yes/SNP Tetralogy of Fallot No No No
8 M 10y 1m Yes/FISH Aortic arch disruption + VSD + ASD Yes Yes Yes
9 F 8y 8m Yes/FISH No No Yes No
10 F 18y 11m Yes/SNP Tetralogy of Fallot No Yes No
11 M 8m Yes/SNP VSD Yes Yes Yes
12 F 12y 11m Yes/FISH Pulmonary atresia No Yes No
13 F 5y 2m No None Yes Yes Yes
14 M 8y 1m Yes/FISH Truncus arteriosus + VSD + ASD Yes Yes No
VSD - ventricular septal defect; ASD - atrial septal defect; FISH – Fluorescence In Situ Hybridization, SNP - single nucleotide polymorphisms HypoCa++ -
hypocalcemiae; Facial abnorm. – facial abnormalities.
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866occurred in the first year of life, before cardiac surgery.
Currently, none of them has any infection.
Laboratory findings
Five (35.8%) patients had hypocalcemia and four of them
were under treatment for hypoparathyroidism. One had
neonatal hypothyroidism since birth and is currently
receiving hormonal treatment. No thyroid autoantibodies
were found in any patients. All patients currently have
normal leukocyte counts, but two have low lymphocyte
counts, below the normal range for their age. These data are
shown in Table 2.
DISCUSSION
Patients with 22q11.2 deletion syndromes, such as the
velocardiofacial, Shprintzen and DiGeorge Syndromes may
have several clinical abnormalities and different degrees of
organ commitment.
12 The syndromes received the name of
the author that first described each one separately. Later,
with the advance of the diagnostic methods in the field of
genetics, it was found that the 22q11.2 chromosome was
deleted in all of them. They are currently grouped as ‘‘the
22q11.2 deletion syndromes’’ because of the difficulties in
choosing a single term.
13
The 22q11.2 deletion is the most common human
chromosome deletion, and its incidence is about 1:3000 live
births.
13 In this study, held in a teaching hospital and
reference center for primary immunodeficiency, the number
of patients available for inclusion in the study was small,
which confirmed the difficulty that physicians have in
diagnosing it and determining phenotypes.
The distribution of patient age in this series corroborates
the difficulty of diagnosing DGS: only 28.5% of the patients
were younger than 4 years, and most were older.
Currently, 180 clinical signs and symptoms, such as
physical and behavioral abnormalities, have been described,
but typical findings are not found in all cases.
14 The facial
phenotype, although easily recognized, may be subtle in
some patients, and growth of the face and consequent
accentuation of abnormalities become more noticeable as
they grow older. DGS diagnoses are based on a set of
clinical findings or 22q11.2 deletion, but 22q11.2 deletion is
only investigated when there are signs suggesting that the
patient may have the syndrome.
During the selection of patients in this study, the 22q11.2
deletion was detected in all but 1 subject. This patient,
without heart disease, had a severe cleft palate that required
several corrective surgeries, a small number of lymphocytes,
and a history of neonatal hypocalcemia.
Diagnosis becomes more difficult when a patient with
classic features of velocardiofacial syndrome or DGS has no
evidence of deletion by FISH. A point mutation, which has
been described in a few patients, might be present in T-box 1
(TBX1).
15 This mutation, a deletion that is too small to be
detected by standard FISH, or a non-chromosome 22 cause
can also be associated with the same clinical manifestations
as in chromosome 22q11.2 deletion syndrome.
Recently, MLPA–HD (multiplex ligation dependent probe
amplification with high-density) was reported
16 as a
technique that detects copy number changes at 37 loci on
velocardiofacial syndrome, the cat eye syndrome, and more
distal regions in 22q11 that have been deleted. Novel and
variant chromosome 22 aberrations have been detected by
this methodology along with the common recurrent dele-
tions associated with DiGeorge syndrome and velocardio-
facial syndrome. Some authors described patients with
relevant phenotypic characteristics where karyotype and
FISH were normal. Only MLPA with high density analysis
can detect uncommon deletions and establish the clinical
diagnosis of 22q11 deletion.
16,17
The International Union of Immunological Societies
Primary Immunodeficiency Diseases Classification Commit-
tee
7 proposed criteria to help to establish the diagnosis of
DGS. These criteria refer primarily to immune disorders and
include the number of circulating T cells and the most
frequent clinical characteristics, such as hypoparathyroi-
dism, conotruncal malformation, facial abnormalities, and
chromosomes 22q11.2 or 10p deletion.
Oskarsdottir et al.
18 conducted a retrospective study with
100 patients that had DGS and reported the clinical findings
of patients diagnosed before and after 2 years of age. The
frequency of delayed diagnoses, also reported in their
study, according to age groups was: 26% in the neonatal
period; 17% between 2-5 years; 41% between 6-12 years; and
16% in adolescence, i.e., between 13-16 years. The mean age
at diagnosis was 6.7 years. Heart disease was the finding
that most frequently led to the diagnosis of DGS at any age,
which was similar to our findings. For children diagnosed
before the age of 2, recurrent infections and thymic
Table 2 - Laboratory data of 14 patients with DGS.
Patient Free-T4 ng/dL TSH mU/mL
Parathyroid
hormone pg /Ml
Ionic
calcium mol/L
Total calcium
mg/dL
Phosphorus
mg/dL
Leucocytes
Cels/mL
1 0.98 1.49 36 1.18 NP 6.1 9600
2 1.03 1.55 34 NP 8.9 4.9 9500
3 1.16 2.98 9* 1.29 8.9 6.6 2900
4 1.37 2.04 59 NP NP NP 5900
5 1.41 5.29 48 NP 8.9 5.3 6400
6 1.30 3.01 53 1.29 NP 4.4 13400
7 1.23 1.15 62 NP 8.5 5.2 4900
8 1.08 4.53 8* 1.22 NP 5.5 7500
9 1.22 5.30 48 1.25 NP 5.6 8000
10 1.07 1.75 NP NP 8.4 4.3 9400
11 1.23 0.90 15* 1.09 NP 7.01 12400
12 1.48 3.81 58 1.16 NP 4.5 5780
13 1.21 4.83 13* 1.18 8.6 6.5 6050
14 1.16 0.76 39 1.31 NP 4.7 5100
NP – Not performed; *values below normal range;
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867hypoplasia were the most frequent findings, followed by
hypocalcemia. In the group that was diagnosed later,
recurrent infections, soft palate defects, and delayed
language acquisition were the most important signs and
symptoms. Facial abnormalities were the least frequent in
the two groups, which confirms the observation that these
changes are established over a span of years.
18
The comparison of our results with findings reported by
Oskarsdottir
18 revealed that only 28% of the patients were
diagnosed before the age of four years, and that heart
malformations were the most prevalent findings, although
cardiac defects were not the reason for referral to our
institution. Jiang et al. suggested that even isolated
congenital heart disease has a strong association with
DGS, and that 22q11.2 deletion should be investigated in
such cases.
5
The frequency of cardiac malformations in patients with
DGS ranges from 49% to 83%. Conotruncal defects are the
most commonly-seen heart diseases, which suggests that
patients may have the tetralogy of Fallot. In the Brazilian
patients described here, the tetralogy of Fallot was found in
50% of the patients, in agreement with data in the
literature.
19,20 The 22q11.2 deletion should be investigated
in all patients with heart malformations, such as tetralogy of
Fallot, disrupted aortic arch, septal defects, and truncus
arteriosus. This is one of the reasons why pediatric
cardiology centers, where the earliest diagnoses are made,
often report case series.
21,22 This practice does not seem to
be usual in our country yet; the number of patients that
undergo cardiac surgery to correct conotruncal defects is
significant, the number of referrals to our service is small,
and reports of patients with DGS are still scarce.
Our patients were older, and mouth, eye, and tooth
abnormalities, as well as the perception of impaired speech
development and behavior, are more easily noticed, as
related by Butts.
23 In schoolchildren, short stature, long
fingers, long face, and a cylindrically-shaped nose are
enough to raise the hypothesis of DGS.
Behavioral, neurological and psychiatric disorders are
frequent in this syndrome. Two patients described here had
symptoms of depression and required medication. Both
patients underwent psychotherapy; despite treatment, they
still do not have good school performance, and their family
relations are inadequate. According to some authors, these
patients should be followed for a long time, because
depression and anxiety may precede the establishment of
psychoses.
24
When first described, DGS was characterized by severe
immunodeficiency at birth. Other clinical features were not
given much attention. The early onset of recurrent infections
due to severe immunodeficiency is no longer the main
clinical feature of DGS, because only patients with complete
DGS have an increased susceptibility to infection. The
number of lymphocytes may be normal, and immune
disorders may appear only in adulthood. Currently, other
clinical signs and symptoms are also important, such as
neonatal hypocalcemia, hypothyroidism, and conotruncal
defects, even in the absence of facial abnormalities or
recurrent infections.
Infants with DGS may have breastfeeding difficulties due
to several factors, such as hypotonia, cardiac problems, and
airway obstruction secondary to jaw malformations. Many
cases are not detected at birth or in childhood because DGS
is a progressive disease and clinical signs that may appear
later in life. At least 30% of the patients do not have heart
defects, and many cardiac malformations, such as right-
sided aorta, are ‘‘silent’’ anomalies and have no obvious
clinical signs or symptoms. Therefore, a diagnosis is only
made if a specific genetic study is performed.
14
CONCLUSION
Pediatricians, neonatologists, ENTs, and cardiac surgeons
should be aware of the possible presence of congenital heart
defects, especially conotruncal defects, neonatal hypocalce-
mia, and defects in the palatal region at birth, which may be
detected soon after birth. Other signs and symptoms, such
as facial abnormalities and impaired development, may
appear only years later and delay the diagnosis. This is the
first report of Brazilian patients with DGS and, although the
frequency of DGS is high, few patients with a confirmed
diagnosis are followed up.
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